Circulating Neuroendocrine Transcripts and Gene Cluster Analysis Predict the Efficacy of PRRT Abstract #1916

Introduction: Prediction of PRRT efficacy is critical. We tested a blood-based multigene NET transcript analysis (NETest) to predict efficacy in 2 PRRT-treated NET cohorts. The algorithm comprises >50 genes + clusters of growth factor signaling (GFS) and metabolism (MTB).
Aim(s): To predict efficacy of PRRT.
Materials and methods: We studied 2 independent 177Lu-PRRT-treated groups: #1 (n= 72), median total activity 18.5GBq (6.5-27.8) and #2 (n= 41), 24.5GBq (11.4-29.7, 24 evaluable pts). At baseline: Ki67, SSR imaging (SRI), CgA (ELISA), and NETest (qRT-PCR - multianalyte algorithmic analyses). Using #1 we mathematically devised a predictive response index (PRI) of NETest (MTB+GFS) & Ki67. We then assessed PRI in #2. RECIST criteria were used. Statistics: multiple regression, Kaplan-Meier survival, Chi2.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Lisa Bodei
Keywords: PRRT, efficacy

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1228 Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy
Introduction: PRRT is an effective therapy for NETs since the majority over-express SSRs. Typically, well or moderately differentiated NETs (G1/G2) are treated. Imaging and CgA are used to evaluate response but both RECIST criteria and CgA have limitations.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Paganelli G, Kidd M, Severi S, ...
#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Mark Kidd
Authors: Bodei L, Kidd M, Severi S, Drozdov I, ...
Keywords: NETest, PRRT
#2216 Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker
Introduction: We have developed a blood-based tool (gene expression analysis and tumor grade) for predicting PRRT efficacy.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Professor Mark Kidd
#949 An Analysis of Toxicity after Peptide Receptor Radionuclide Therapy (PRRT) in 807 Patients: Determination of the Limited Predictive Role of Clinical Factors
Introduction: PRRT with 90Y-octreotide (Y) and 177Lu-octreotate (Lu) is well-tolerated.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Lisa Bodei
Authors: Bodei L, Kidd M, Grana C, Severi S, ...
Keywords: NET, PRRT, risk, toxicity
#1879 A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs
Introduction: Clinical assessment has limited prognostic ability. Mathematical tools –nomograms- that incorporate multiple parameters are more effective. Novel transcriptomic data has added value in defining NET biology in tissue and blood. A blood multigene expression analysis test is effective as a molecular prognostic marker for PFS.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Professor Mark Kidd
Authors: Kidd M, Bodei L, Severi S, Drozdov I, ...